China Net Finance news on October 16 (reporter Ye Qian Hu Jingling) 3 months after landing on the science and technology innovation board, Warner Pharmaceutical Factory director, deputy general manager, board secretary Li Mengchun resigned. On the evening of the 14th, Warner Pharmaceutical Factory issued an announcement that Li Mengchun would undertake other work in the company after applying for resignation due to job changes. As of the date of the announcement, Li Mengchun directly or indirectly held 1.88 million shares in the company. According to the closing price of 40 yuan on October 15, Li Mengchun holds a market value of about 75.2 million yuan.
According to the prospectus of Warner Pharmaceuticals, since November 2015, Li Mengchun has served as a director, deputy general manager and secretary of the board of directors of Warner Pharmaceuticals, and Li Mengchun's annual salary in Warner Pharmaceuticals in 2020 is 242,100 yuan.
In 2016, Warner Pharmaceuticals applied for listing on the Growth Enterprise Market (GEM), but was suspended from review due to incomplete application documents, and in April 2020, it moved to the Science and Technology Innovation Board. On July 13 this year, Warner Pharmaceutical Factory was listed on the Science and Technology Innovation Board, the company's opening price on the first day of listing was 61.2 yuan, the highest stock price had reached 69.98 yuan, and then broke, on September 29, Warner Pharmaceuticals' stock price fell to 37.96 yuan, down 84.11% from the highest price.
In addition to the departure of the secretary of the board of directors, during the IPO of Warner Pharmaceutical Factory, the Shanghai Stock Exchange focused on the departure of the company's financial director. On March 16, 2018, the then financial director Tang Yinhui applied for resignation for personal reasons, Warner Pharmaceutical Factory said that Tang Yinhui has been the financial director since September 2015, and in March 2018, Warner Pharmaceutical Factory withdrew the issuance application from the China Securities Regulatory Commission, after which Tang Yinhui applied to leave the company from the company from the comprehensive factors of personal income, business platform, development prospects and other factors, and instead joined Wharf (Changsha) Real Estate Co., Ltd. as assistant financial audit manager, seeking better personal development opportunities.
Warner Pharmaceutical Factory is a high-tech enterprise with the research and development, production and sales of chemical APIs, chemical preparations and traditional Chinese medicine preparations as its main business, and has the production capacity of tablets, capsules, granules, powders, dry suspensions, inhalation solutions, small-volume injections, eye drops, lyophilized powder injections and other dosage forms and chemical APIs.
According to Zhonghong Network, the China Judgment Document Network disclosed that Xu Yan, vice chairman of Warner Pharmaceutical Factory, had been involved in the "He Aidong bribery case" for "bribery". On September 9, 2016, the Yuelu District People's Court of Changsha City, Hunan Province, against He Aidong, former deputy chief engineer of Hunan Torch Entrepreneurship Center and director of the Project Supervision Department, for abusing his power and privately dividing state-owned assets, showed that in the first half of 2009, Xu Moujia, the general manager of Boya Company, found the defendant He Aidong and requested attention to the preparation of the application materials and the evaluation of the project for his company's national innovation project of "developing for gacycline and powder needles", and agreed on the proportion of benefit fees. Later, under the care of defendant He Aidong, the project successfully passed the project approval review and received 900,000 yuan of state funding at the end of 2010. At the end of 2010 or the beginning of 2011, in order to express his gratitude, Xu Moujia gave the defendant He Aidong a one-time cash of RMB 120,000 on the south side of the gate of the Dongtang Telecommunications Bureau in Changsha.
Zhonghong Network said in the report, "Obviously, the 'Xu Mou' in the 'He Aidong bribery case' is an executive of Warner Pharmaceutical. ”
(From China Judgment Documents Network)
Media Golden Light also mentioned in the report that in the prospectus, Warner Pharmaceutical Factory's disclosure of vice chairman Xu Yan's resume can be described as "half-covered by the pipa". The prospectus discloses the resumes of other directors, except for Warner Pharmaceutical Factory and its subsidiaries, generally in accordance with the requirements of the norms of information disclosure, using the full name of the standard in the industrial and commercial information, except for Xu Yan's experience in Boya Pharmaceutical. According to the prospectus, from December 2001 to April 2015, Xu Yan was an executive director of Boya Pharmaceutical.
According to industrial and commercial information, the only person who meets the establishment time of Boya Pharmaceutical in the prospectus is Changsha Boya Pharmaceutical Technology Development Co., Ltd., which was established in December 2001 and has been deregistered in November 2018, and the former executive director and general manager is Xu Yan, which was changed to Li Ping in April 2015. Judging from the above information, this Changsha Boya Pharmaceutical Technology Development Co., Ltd. is likely to be the real body of "Boya Pharmaceutical" disclosed in the prospectus.
It is worth mentioning that the name of "Changsha Boya Pharmaceutical Technology Development Co., Ltd." appears in the related party disclosed in the prospectus of Warner Pharmaceutical Factory, which is a 40% shareholding enterprise held by Xu Yan's sister, which also seems to confirm that the Boya Pharmaceutical where Xu Yan once worked is Changsha Boya Pharmaceutical Technology Development Co., Ltd.
Media Golden Light said that combined with the prospectus of Warner Pharmaceutical Factory and the industrial and commercial information of Boya Pharmaceutical, is the subject of this bribery case Xu Yan, vice chairman of Warner Pharmaceutical Factory? Is Warner Pharmaceuticals' concealment of Boya Pharma's background also related to this case? According to the information disclosure requirements, Warner Pharmaceutical Factory should correspond the abbreviation of Boya Pharmaceutical to the full name in the "General Interpretation" section, but the company did not clearly state that Boya Pharmaceutical is Changsha Boya Pharmaceutical Technology Development Co., Ltd., but instead half-concealed in the resume of the vice chairman.
(Editor-in-Charge: Chu Dye Xi)